Arrowhead Research | ARWR - Current Liabilities

Stock Price
63.59
Daily Change
-0.27 -0.42%
Monthly
-5.93%
Yearly
219.55%
Q1 Forecast
61.62

Arrowhead Research reported $347.42M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Anika Therapeutics USD 19.09M 3.01M Sep/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Ligand Pharmaceuticals USD 30.54M 34.2M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Novartis USD 32B 286M Sep/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 86.48M 9.6M Sep/2025